Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el 

Ab­b­Vie said Wednes­day evening it plans to pay $8.7 bil­lion to ac­quire neu­ro­science drug­mak­er Cerev­el Ther­a­peu­tics in a deal that comes just six days af­ter the Chica­go-area Big Phar­ma said it would pay $10.1 bil­lion for Im­muno­Gen.

Ab­b­Vie had on­ly made one M&A deal this year be­fore an­nounc­ing the Im­muno­Gen ac­qui­si­tion, mak­ing a small $110 mil­lion up­front pay­ment for a Parkin­son’s dis­ease start­up. Now, it has made the third- and fourth-largest bio­phar­ma M&A deals of 2023 so far.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER